Mitiglinide calcium 207844-01-7

CAS：

207844-01-7

含量：

99%

包装：

1Kg铝箔袋

Mitiglinide calcium
Chinese name mitiglinide calcium
Chinese synonyms Mitiglinide (calcium) (dihydrate) benzyl (cis-perhydroisoindolecarbonyl) Calcium propionate dihydrate, mitiglinide calcium hydrate, mitiglinide calcium hydrate (calcium salt, hydrate), mitiglinide calcium dihydrate, mitiglinide calcium dihydrate
English name no. The strong and short-acting characteristics avoid the occurrence of adverse reactions such as hypoglycemia, and there are no gastrointestinal adverse reactions of glycosidase inhibitors, making it a more competitive postprandial blood sugar regulator in the market. Mitiglinide calcium only stimulates the pancreas to secrete insulin quickly and briefly when eating. It has a quick onset and short duration of action. Traditional oral diabetes drugs continue to stimulate insulin secretion and overstimulate it, especially between two meals. often make patients feel hungry. When taking sulfonyl pulse drugs, patients are even encouraged to take snacks between meals to metabolize excess insulin. This extra eating causes patients to gain weight, and they are often obese to begin with. Mitiglinide calcium is the third meglitinide-type antidiabetic drug after repaglinide and nateglinide. It was successfully developed by Japan's Jusheng Pharmaceutical Co., Ltd. and was approved by the Ministry of Health and Welfare of Japan on March 21, 2020. It was first used in Japan in March 2019 Marketed for the treatment of type 2 diabetes. It is a first-line treatment drug for patients with early-stage and mild-to-severe type Ⅱ diabetes, and has the reputation of in vitro pancreatic islet. Clinical trials have shown that this type of drug is superior to other hypoglycemic drugs in terms of efficacy and safety so far. It is a new type of fast-acting mealtime blood sugar regulator that promotes the secretion of insulin by islet cells. It is suitable for patients who cannot be effectively controlled by diet and exercise therapy. For patients with hyperglycemic diabetes, it is mainly used to control postprandial hyperglycemia. This product can close the + channel on islet cells, increase the concentration of + in the cells, and degranulate the insulin-containing vesicles outside the cells, thus stimulating the secretion of insulin. In vitro experiments show that mitiglinide calcium can stimulate isolated hamster islet cells to secrete insulin. Electrophysiological studies have shown that this product can inhibit the opening of sensitive + channels. At a concentration of /, the channel can be completely blocked and can stimulate + to enter cells. In the presence of glucose, mitiglinide calcium can dose-dependently stimulate insulin secretion from rat isolated pancreas and isolated perfused pancreas.
Mitiglinide and nateglinide are both fast-acting insulin secretion-stimulating drugs, but mitiglinide shows a more significant effect on improving postprandial hyperglycemia. This difference in efficacy is reflected in the fact that mitiglinide's effect in promoting insulin secretion from cells is about twice that of nateglinide, and its effect on promoting insulin secretion in type 2 diabetic animals is more significant than that of nateglinide.
Usage: Meglitinide hypoglycemic drugs
Content
Packaging in aluminum foil bags
Appearance: white powder
Price yuan/